Obsessive-compulsive disorder: Diagnosis and treatment

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 18, 1999, Pages 27-32

  Goodman, Wayne K ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HALOPERIDOL; NEUROLEPTIC AGENT; PAROXETINE; PINDOLOL; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANTICHOLINERGIC EFFECT; ANXIETY NEUROSIS; ARTICLE; BEHAVIOR THERAPY; COMORBIDITY; DEPRESSION; HUMAN; OBSESSION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SIDE EFFECT; TREATMENT PLANNING;

ANXIETY DISORDERS; BEHAVIOR THERAPY; CLINICAL TRIALS; COMBINED MODALITY THERAPY; COMORBIDITY; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HALOPERIDOL; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PINDOLOL; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0032875393     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
2. Karno M, Golding JM, Sorenson SB, et al. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988;45:1094-1099
3. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19
4. Sasson Y, Zohar J, Chopra M, et al. Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry 1997:58(suppl 12):7-10
5. Nymberg JH, Van Noppen B. Obsessive-compulsive disorder: a concealed diagnosis. Am Fam Physician 1994;49:1129-1137
6. Rasmussen SA, Eisen JL. Epidemiology and differential diagnosis of obsessive compulsive disorder. J Clin Psychiatry 1994;55(10, suppl):5-14
7. Stein MB, Forde DR, Anderson G, et al. Obsessive-compulsive disorder in the community: an epidemiologic survey with clinical reappraisal. Am J Psychiatry 1997;134:1120-1126
8. Weissman MM, Bland RC, Canino GJ, et al. Cross national epidemiology of obsessive-compulsive disorder. J Clin Psychiatry 1994;55(3, suppl): 5-10
9. Zetin M, Kramer MA. Obsessive-compulsive disorder. Hosp Community Psychiatry 1992;43:689-699
10. Leonard HL, Swede SE, Lenane MC, et al. A 2-to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry 1993;50:429-439
11. Rasmussen SA, Eisen JL. Treatment strategies for chronic and refractory obsessive-compulsive disorder. J Clin Psychiatry 1997;58(suppl 13):9-13
12. Swedo SE, Rapoport JL, Leonard H, et al. Obsessive-compulsive disorder in children and adolescents: clinical phenomenology of 70 consecutive cases. Arch Gen Psychiatry 1989;46:335-341
13. Koran LM, Thienemann ML, Davenport R. Quality of life for patients with obsessive-compulsive disorder. Am J Psychiatry 1996;153:783-788
14. Hollander E, Greemvald S, Neville D, et al. Uncomplicated and comorbid obsessive-compulsive disorder in an epidemiologic sample. Depress Anxiety 1996/1997;4:111-119
15. Hollander E. Obsessive-compulsive disorder: the hidden epidemic [introduction]. J Clin Psychiatry 1997;58(suppl 12):3-6
16. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. Arch Gen Psychiatry 1989;46:1006-1016
17. Kim SW, Dysken MW, Kuskowski M. The Yale-Brown Obsessive-Compulsive Scale: a reliability and validity study. Psychiatry Res 1990;34: 99-104
18. Dolberg OT, Iancu I, Sasson Y, et al. The pathogenesis and treatment of obsessive-compulsive disorder. Clin Neuropharmacol 1996;19:129-147
19. Ellingrod VL. Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature. Pharmacotherapy 1998;18:936-960
20. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-738
21. Leonard HL. New developments in the treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(suppl 14):39-45
22. Goodman WK, Price LH, Rasmussen SA, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder. Arch Gen Psychiatry 1989;46:36-14
23. Zohar J, Judge R, and the OCD Paroxetine Study Investigators. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996;169:468-474
24. Goodman WK, Ward H, Kablinger A, et al. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. J Clin Psychiatry 1997;58(suppl 5):32-49
25. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-295
26. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:53-60
27. Tollefson GD, Rampey AH, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-567
28. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol 1997;17:267-271
29. Flament MF, Bisserbe J-C. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies. J Clin Psychiatry 1997;58 (suppl 12):18-22
30. Freeman CPL, Trimble MR, Deakin JFW, et al. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994;55:301-305
31. Jenike MA, Baer L, Greist JH. Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. J Clin Psychopharmacol 1990;10:122-124
32. Pigott TA, Pato MT, Bernstein SE, et al. Controlled comparison of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1990;47:926-932
33. Blier P, Bergeron R. Use of pindolol to potentiate antidepressant medication. J Clin Psychiatry 1998;59(suppl 5):16-23
34. 1A antagonists. Trends Neurosci 1996;19:378-383
35. Bordet R, Thomas P, Dupuis B, et al. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Am J Psychiatry 1998;155: 1346-1351
36. Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996;41:201-210
37. Moreno FA, Gelenberg AJ, Bachar K, et al. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry 1997;58:437-439
38. McDougle CJ. Update on pharmacologic management of OCD: agents and augmentation. J Clin Psychiatry 1997;58(suppl 12):11-17
39. Wheadon DE, Bushnell WD, Steiner M. A fixed-dose comparison of 20, 40, or 60 mg paroxetine or placebo in the treatment of obsessive-compulsive disorder. Presented at the 32nd annual meeting of the American College of Neuropsychopharmacology; Dec 13-17, 1993; Honolulu, Hawaii
40. Steiner M, Bushnell WD, Gergel I. Long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Presented at the 1995 annual meeting of the American Psychiatric Association; May 20-25, 1995; Miami, Fla
41. Goodman WK, McDougle CJ, Barr LC, et al. Biological approaches to treatment-resistant obsessive compulsive disorder. J Clin Psychiatry 1993; 54(6, suppl):16-26
42. Black DW, Monahan P, Gable J, et al. Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. J Clin Psychiatry 1998;59:420-425
43. Hollander E, DeCaria CM, Schneier FR, et al. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. J Clin Psychiatry 1990;51:119-123
44. Jenike MA. Augmentation strategies for treatment-resistant obsessive-compulsive disorder. Harvard Rev Psychiatry 1993;1:17-26
45. Grady TA, Pigott TA, L'Heureux F, et al. Double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 1993;150:819-821
46. Pigott TA, L'Heureux F, Hill JL, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:11-18
47. Eisenberg J, Asnis G. Lithium as an adjunct treatment in obsessive-compulsive disorder [letter]. Am J Psychiatry 1985;142:663
48. McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991;11:175-184
49. Pigott TA, Pato MT, L'Heureux F, et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1991; 11:242-248
50. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995;56:423-429
51. Ravizza L, Barzega G, Bellino S, et al. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull 1996;32:677-682
52. McDougle CJ, Goodman W, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:302-308
53. Saxena S, Wang D, Bystritsky A, et al. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-306
54. Warneke L. Intravenous clomipramine therapy in obsessive-compulsive disorder. Can J Psychiatry 1989;34:853-859
55. Koran L, Faravelli C, Pallanti S. Intravenous clomipramine for obsessive-compulsive disorder [letter]. J Clin Psychopharmacol 1994;14:216-218
56. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1997;154:396-401
57. Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine. Arch Gen Psychiatry 1998;55:918-924
58. Hollander E. Obsessive-compulsive disorder-related disorders: the role of selective serotonergic reuptake inhibitors. Int Clin Psychopharmacol 1996; 11(5, suppl):75-87
59. Petter T, Richter MA, Sandor P. Clinical features distinguishing patients with Tourette's syndrome and obsessive-compulsive disorder from patients with obsessive-compulsive disorder without tics. J Clin Psychiatry 1998; 59:456-459
60. Swedo SE, Leonard HL, Kiessling LS. Speculations on antineuronal antibody-mediated neuropsychiatrie disorders of childhood. Pediatrics 1994; 93:323-326
61. Coffey BJ, Miguel EC, Savage CR, et al. Tourette's disorder and related problems: a review and update. Harvard Rev Psychiatry 1994;2:121-132
62. George MS, Trimble MR, Ring HA, et al. Obsessions in obsessive-compulsive disorder with and without Gilles de la Tourette's syndrome. Am J Psychiatry 1993;150:93-97
63. Swedo SE, Leonard HL, Mittleman BB, et al. Identification of children with pediatric autoimmune neuropsychiatrie disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am J Psychiatry 1997;154:110-112
64. Ayoub EM. Resurgence of rheumatic fever in the United States. Postgrad Med 1992;92:133-142
65. Swedo SE. Sydenham's chorea: a model for childhood autoimmune neuropsychiatric disorders. JAMA 1994;272:1788-1791
66. Allen AJ, Leonard HL, Swedo SE. Case study: a new infection-triggered, autoimmune subtype of pediatric OCD and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1995;34:307-311
67. Swedo SE, Leonard HL, Schapiro MB, et al. Sydenham's chorea: physical and psychological symptoms with St Vitus dance. Pediatrics 1993;91: 706-713